Hypertrophic obstructive cardiomyopathy
Conditions
Interventions
Group 1: Patients with the Diagnosis of hypertrophic obstructive cardiomyopathy
Sponsors
Herzzentrum der Uniklinik Köln
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients - with a current or prior diagnosis of hypertrophic obstructive cardiomyopathy (HOCM) according to current guidelines, and - who have received guideline-based treatment with non-specific negatively inotropic medications and/or have undergone septal reduction therapy, and - who present at the participating center during the period in which mavacamten was used there as part of the Compassionate Use Program (CUP), or from July 1, 2023, at the latest.
Exclusion criteria
Exclusion criteria: Participation not desired, no informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| •Proportion of patients in Germany initially treated with a myosin inhibitor •Functional clinical improvement based on NYHA + CCS class •Hospitalizations due to heart failure •New onset or recurrence of atrial fibrillation •Death | — |
Secondary
| Measure | Time frame |
|---|---|
| • Echocardiography and MRI parameters of disease severity • Relevant changes in cardiac biomarkers NT-proBNP + Troponin T • Decrease in LV function to <50% on echocardiography | — |
Countries
Germany
Contacts
Public ContactLeni Katharina Seuthe
Herzzentrum der Uniklinik Köln
Outcome results
None listed